LungLife AI: Edison Open House Healthcare 2022

LungLife AI: Edison Open House Healthcare 2022

LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.

• Please explain the importance of the early detection of lung cancer.
• What are the current issues with screening?
• How does LungLife help to overcome these problems?
• How does artificial intelligence (AI) help?
• How will people be prompted to get a test earlier, if symptoms only occur later in the disease?
• Following the recent announcement of your US PLA code, how is this significant to your commercialisation?
• Can your lung cancer product be adapted for other cancers?
• Tell us about the White Ribbon Project and its aim to reduce the stigma around lung cancer.
• Which milestones should investors focus on in the coming year?


You may also be interested in these:

TMT

Checkit – executive interview

Investment Companies

International Public Partnerships - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free